Vyome Holdings, Inc.
HINDVyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.
- Revenue
- +67.6%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
Follow HIND
Alert me
Vyome Holdings, Inc. (HIND) EV/Sales
As of Nov 20, 2026, Vyome Holdings, Inc. (HIND) trades at a EV/Sales of 12.7×. Over the past ten years it has ranged from −10.7× (September 2025) to 440,315,327× (June 2017); the current reading is higher than 37% of that period. That is above the Biotechnology industry median of 8.0× and above the Healthcare sector median of 3.1×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 48.5× | 5,398.46% |
| FY2024 | 0.9× | — |
| FY2023 | −0.3× | — |
| FY2022 | 0.5× | — |
| FY2021 | −1.7× | — |
| FY2020 | 451,057× | (80.98%) |
| FY2019 | 2,371,429× | (37.06%) |
| FY2018 | 3,767,621× | (96.41%) |
| FY2017 | 104,890,150× | 5.78% |
| FY2016 | 99,162,852× | 118.34% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 45.3× | (18.44%) |
| Jun 2026 | 55.5× | 51.76% |
| Mar 2026 | 36.6× | (24.60%) |
| Dec 2025 | 48.5× | 94.83% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LSTA Lisata Therapeutics, Inc. compare | −18.0× |
| TCRX TScan Therapeutics, Inc. compare | −4.0× |
| LEXX Lexaria Bioscience Corp. compare | 5.6× |
| HIND Vyome Holdings, Inc. | 12.7× |
| GDTC CytoMed Therapeutics Limited compare | — |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| PBM Psyence Biomedical Ltd. compare | — |
| AEON AEON Biopharma, Inc. compare | — |
| BIVI BioVie Inc. compare | — |
| Biotechnology industry median | 8.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.9× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)